Specificity and Function of CD25+ Regulatory T Cells

CD25 调节性 T 细胞的特异性和功能

基本信息

  • 批准号:
    8436272
  • 负责人:
  • 金额:
    $ 39.62万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-04-01 至 2015-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This project's goal is to use a well-characterized model system to define processes governing the formation and activity of CD4+CD25+Foxp3+ regulatory T (Treg) cells. The proposal will make use of existing lineages of transgenic mice expressing the influenza virus hemagglutinin (HA) under the control of a variety of promoters (HA Tg mice) and/or HA-specific T cell receptors with varying affinities and specificities for the HA (TCR Tg mice). By analyzing double transgenic mice co-expressing HA-specific TCRs and neo-self HA peptides (TCRxHA Tg mice), we have shown that highly specific interactions with HA-derived peptides can induce thymocytes to undergo selection to become Treg cells that suppress conventional CD4+ T (Tconv) cell responses in vitro, and can modify immune responses in vivo. We have shown that the formation of these Treg cells is highly sensitive to variations in the amount of the HA that is expressed in different HA Tg lineages, and that expression of HA selectively by antigen presenting cells in one of these lineages (designated HACII mice) induces the spontaneous development of inflammatory arthritis in TCRxHACII mice despite the presence of antigen-specific Treg cells. We will use this unique model system to examine how TCR specificity directs Treg cell formation and determines the capacity of Treg cells to modulate anti-self and anti-viral immune responses. In Aim 1 we will examine how TCR recognition of self-peptides shapes Treg repertoire formation. We will modulate the reactivity of the TCR for self-peptides and determine the effects on thymic Treg cell development in TCRxHA Tg mice, and will use adoptive transfer approaches to examine the development of Treg cells in the periphery of HA Tg mice under various conditions. In Aim 2 we will examine how Treg specificity for self-peptides shapes anti-viral immunity. We will analyze the ability of Treg cells from TCRxHA Tg mice to modulate antibody responses to influenza viruses with which they possess varying degrees of crossreactivity, and examine HA Tg mice that do not co-express TCR transgenes for their frequencies of virus- specific CD4+ Treg and Tconv cells. In Aim 3 we will determine how TCR specificity impacts the ability of Treg cells to prevent autoimmune arthritis. We will either deplete Treg cells, or add Treg cells with varying degrees of reactivity with the HA to pre-arthritic TCRxHACII mice, and determine the effects on cellular processes that accompany arthritis development. We will also analyze the expansion and differentiation of Treg cells with varying degrees of reactivity for the HA following transfer into HACII or TS1xHACII mice. These studies will provide fundamental insights into the mechanisms of immune repertoire formation and tolerance. They will enhance our understanding of the role immune regulation plays in anti-viral immunity and how its failure can contribute to autoimmunity, and will enhance the ability of Treg cells to b exploit in diagnostic therapeutic settings.
描述(由申请人提供):该项目的目标是使用一个特征良好的模型系统来定义控制CD4+CD25+Foxp3+调节性T (Treg)细胞形成和活性的过程。该提案将利用现有的转基因小鼠谱系,在多种启动子(HA Tg小鼠)和/或HA特异性T细胞受体的控制下表达流感病毒血凝素(HA),这些T细胞受体对HA具有不同的亲和力和特异性(TCR Tg小鼠)。通过分析双转基因小鼠共表达HA特异性TCRs和新自我HA肽(TCRxHA Tg小鼠),我们发现,与HA衍生肽的高度特异性相互作用可以诱导胸腺细胞选择成为Treg细胞,从而在体外抑制常规CD4+ T (Tconv)细胞反应,并在体内修饰免疫反应。我们已经证明,这些Treg细胞的形成对不同HA Tg谱系中HA表达量的变化高度敏感,并且在这些谱系之一(指定的HACII小鼠)中,抗原呈递细胞选择性地表达HA诱导TCRxHACII小鼠炎症性关节炎的自发发展,尽管存在抗原特异性Treg细胞。我们将使用这个独特的模型系统来研究TCR特异性如何指导Treg细胞的形成,并确定Treg细胞调节抗自身和抗病毒免疫反应的能力。在目标1中,我们将研究自肽的TCR识别如何塑造Treg库的形成。我们将调节TCR对自身肽的反应性,并确定对TCRxHA Tg小鼠胸腺Treg细胞发育的影响,并将使用过继性转移方法来检测不同条件下HA Tg小鼠外周血Treg细胞的发育。在目标2中,我们将研究Treg特异性对自身肽如何影响抗病毒免疫。我们将分析来自TCRxHA Tg小鼠的Treg细胞调节流感病毒抗体反应的能力,因为它们具有不同程度的交叉反应性,并检测不共表达TCR转基因的HA Tg小鼠的病毒特异性CD4+ Treg和Tconv细胞的频率。在Aim 3中,我们将确定TCR特异性如何影响Treg细胞预防自身免疫性关节炎的能力。我们将在患关节炎前的TCRxHACII小鼠中要么消耗Treg细胞,要么添加与HA具有不同程度反应性的Treg细胞,并确定对伴随关节炎发展的细胞过程的影响。我们还将分析转移到HACII或TS1xHACII小鼠后,对HA具有不同程度反应性的Treg细胞的扩增和分化。这些研究将为免疫库形成和耐受性的机制提供基本的见解。它们将增强我们对免疫调节在抗病毒免疫中所起作用的理解,以及它的失败如何导致自身免疫,并将增强Treg细胞在诊断治疗环境中的利用能力。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Thymocyte deletion can bias Treg formation toward low-abundance self-peptide.
  • DOI:
    10.1002/eji.200939709
  • 发表时间:
    2009-12
  • 期刊:
  • 影响因子:
    5.4
  • 作者:
    Picca, Cristina Cozzo;Oh, Soyoung;Panarey, Laura;Aitken, Malinda;Basehoar, Alissa;Caton, Andrew J.
  • 通讯作者:
    Caton, Andrew J.
Flow cytometric profiling of mature and developing regulatory T cells in the thymus.
对胸腺中成熟和发育中的调节性 T 细胞进行流式细胞分析。
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANDREW J CATON其他文献

ANDREW J CATON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANDREW J CATON', 18)}}的其他基金

Regulatory T Cell Activity in Anti-Viral Immunity
抗病毒免疫中的调节性 T 细胞活性
  • 批准号:
    8089285
  • 财政年份:
    2010
  • 资助金额:
    $ 39.62万
  • 项目类别:
Regulatory T Cell Activity in Anti-Viral Immunity
抗病毒免疫中的调节性 T 细胞活性
  • 批准号:
    7746170
  • 财政年份:
    2009
  • 资助金额:
    $ 39.62万
  • 项目类别:
Specificity and Function of CD25+ Regulatory T Cells
CD25 调节性 T 细胞的特异性和功能
  • 批准号:
    7920671
  • 财政年份:
    2009
  • 资助金额:
    $ 39.62万
  • 项目类别:
Hybridoma Facility
杂交瘤设施
  • 批准号:
    7945016
  • 财政年份:
    2009
  • 资助金额:
    $ 39.62万
  • 项目类别:
Hybridoma Facility
杂交瘤设施
  • 批准号:
    7945021
  • 财政年份:
    2009
  • 资助金额:
    $ 39.62万
  • 项目类别:
Specificity and Function of CD25+ Regulatory T Cells
CD25 调节性 T 细胞的特异性和功能
  • 批准号:
    6756805
  • 财政年份:
    2004
  • 资助金额:
    $ 39.62万
  • 项目类别:
Specificity and Function of CD25+ Regulatory T Cells
CD25 调节性 T 细胞的特异性和功能
  • 批准号:
    8044711
  • 财政年份:
    2004
  • 资助金额:
    $ 39.62万
  • 项目类别:
Specificity and Function of CD25+ Regulatory T Cells
CD25 调节性 T 细胞的特异性和功能
  • 批准号:
    7663631
  • 财政年份:
    2004
  • 资助金额:
    $ 39.62万
  • 项目类别:
Specificity and Function of CD25+ Regulatory T Cells
CD25 调节性 T 细胞的特异性和功能
  • 批准号:
    7213400
  • 财政年份:
    2004
  • 资助金额:
    $ 39.62万
  • 项目类别:
Specificity and Function of CD25+ Regulatory T Cells
CD25 调节性 T 细胞的特异性和功能
  • 批准号:
    8240106
  • 财政年份:
    2004
  • 资助金额:
    $ 39.62万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 39.62万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 39.62万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 39.62万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 39.62万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 39.62万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 39.62万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 39.62万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 39.62万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 39.62万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 39.62万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了